AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office

Dow Jones

Jan 24, 2025

By Connor Hart

AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area.

The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business.

The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said.

"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government," Chief Executive Pascal Soriot said.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 23, 2025 14:54 ET (19:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2505028999"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505028999\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505028999?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-24 03:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505028999","market":"fut","top_or_hot":-1,"title":"AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. \n</p>\n<p>\n  The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business. \n</p>\n<p>\n  The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said. \n</p>\n<p>\n  \"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government,\" Chief Executive Pascal Soriot said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2025 14:54 ET (19:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca to Invest C$820 Million to Move to Larger Toronto Office</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca to Invest C$820 Million to Move to Larger Toronto Office\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-24 03:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. \n</p>\n<p>\n  The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business. \n</p>\n<p>\n  The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said. \n</p>\n<p>\n  \"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government,\" Chief Executive Pascal Soriot said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 23, 2025 14:54 ET (19:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505028999","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505028999","pubTimestamp":1737662040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area.The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business.The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said.\"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government,\" Chief Executive Pascal Soriot said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4007":"制药","BK4588":"碎股","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"阿斯利康将投资8.2亿加元迁至更大的多伦多办事处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. \n\n\n  The Anglo-Swedish pharmaceutical giant said Thursday that the move will add 700 high-skilled jobs across all areas of its business. \n\n\n  The investment comes after AstraZeneca last year completed its C$3 billion acquisition of Hamilton, Ontario-based Fusion Pharmaceuticals, which is developing next-generation radioconjugates, a novel drug modality that delivers radiation directly to cancer cells. The company since 2023 has invested C$1.3 billion in Canada, it said. \n\n\n  \"This investment is a reflection of our growing clinical pipeline, our strong belief in Canada's potential as a global hub for life sciences innovation, and the value of public-private collaboration with the Ontario government,\" Chief Executive Pascal Soriot said. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2025 14:54 ET (19:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}